• Na Homolce Hospital in Prague, Czech Republic to become third site for VISABL-VT clinical trial
• Professor Petr Neužil and Dr. Vivek Reddy to lead the trial at Na Homolce
• Expansion into key sites with leading experts in the field of ventricular tachycardia (VT) ablation

Imricor Medical Systems, Inc. (ASX: IMR) is pleased to announce that, with local Ethics Committee approval, the Na Homolce Hospital in Prague, Czech Republic (Na Homolce) is to be the third site to join the VISABL-VT clinical trial. The Principal Investigator (PI) for VISABL-VT at Na Homolce is Professor Petr Neužil, MD, who is the Head of Cardiology and the Director of the Cardiac Arrhythmia Service at Na Homolce, and a world-renowned cardiac electrophysiologist. Also participating in VISABL-VT at Na Homolce is Dr Vivek Reddy, MD, an internationally recognised cardiac electrophysiologist and Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System in New York, USA. Na Homolce Hospital performs up to 3500 catheterisation procedures each year. Imricor's Chair and CEO, Steve Wedan, commented that ventricular tachycardia (VT) ablations are among the most complex and time-consuming procedures performed by electrophysiologists worldwide, and that the difficulties associated with VT ablations and the promise that MRI guidance offers to these procedures are well-known. Imricor's Vice President of Corporate Strategy, Nick Corkill, added that starting with atrial flutter was an important steppingstone for interventional cardiac MRI (iCMR), and VT is the next big step, with MRI guidance enabling the visualization of arrhythmogenic substrates that are hidden to other imaging modalities, opening the door for shorter procedures and better outcomes.